Superior efficacy with XELODA when response matters most in combination therapy1

XELODA plus docetaxel resulted in statistically significant improvements in efficacy compared with docetaxel monotherapy.*

*Open-label, multicenter, randomized trial in 75 centers worldwide of 511 patients with mBC resistant to, or recurring during or after an anthracycline-containing therapy, or relapsing during or recurring within 2 years of completing an anthracycline-containing adjuvant therapy.
†The response rate reported represents a reconciliation of the investigator and IRC assessments performed by the sponsor according to a predetermined algorithm.
 

• Median time to disease progression in patients receiving XELODA plus docetaxel vs docetaxel alone was 186 days (range, 165–198) and 128 days (range, 105–136), respectively (P <.0001).
• XELODA delivered a 3-month improvement in median overall survival when combined with docetaxel, compared with docetaxel alone (P = .0126).

 

Superior survival with XELODA plus docetaxel vs docetaxel alone

‡ Adapted from O'Shaughnessy JA, Am J Oncol Rev, 2002.²
§ XELODA 1250 mg/m2 twice daily intermittently plus docetaxel 75 mg/m2/3 weeks.
|| Docetaxel 100 mg/m2/3 weeks.

XELODA plus docetaxel—An effective combination when your goal is rapid response1

 

REFERENCES

1. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-2823.
2. O'Shaughnessy JA. Superior survival with the combination of docetaxel and capecitabine compared to docetaxel alone in anthracycline-pretreated metastatic breast cancer patients. Am J Oncol Rev. 2002;1(5):280-285.